Effect of posaconazole on the pharmacokinetics of fosamprenavir and vice versa in healthy volunteers

Journal of Antimicrobial Chemotherapy

Volumn 65, Issue 10, 2010, Pages 2188-2194

  Brüggemann, Roger J M ^a   van luin, Matthijs ^a,b   Colbers, Engelina P H ^a   van den dungen, Myrthe W ^a   Pharo, Cristina ^c   Schouwenberg, Bas J J W ^a   Burger, David M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Alysis Zorggroep   (Netherlands)

^c GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Antiretroviral drugs; Azole antifungal drugs; Drug drug interaction; Healthy volunteers; Pharmacokinetic

Indexed keywords

FOSAMPRENAVIR; FOSAMPRENAVIR PLUS RITONAVIR; POSACONAZOLE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG COMPETITION; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFECT; DRUG ELIMINATION; DRUG ERUPTION; DRUG HALF LIFE; DRUG SAFETY; DRUG WITHDRAWAL; EVENING DOSAGE; FEMALE; FLATULENCE; HUMAN; LOOSE FECES; MALE; MAXIMUM PLASMA CONCENTRATION; MORNING DOSAGE; OPEN STUDY; PATIENT COMPLIANCE; PHARMACOKINETICS; PHASE 1 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; PRURITUS; RANDOMIZED CONTROLLED TRIAL;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; ANTIFUNGAL AGENTS; CARBAMATES; CROSS-OVER STUDIES; DRUG INTERACTIONS; FEMALE; HUMAN EXPERIMENTATION; HUMANS; MALE; MIDDLE AGED; PHOSPHORIC ACID ESTERS; SULFONAMIDES; TRIAZOLES; YOUNG ADULT;

EID: 77957226579     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkq280     Document Type: Article

References (33)

1. Tappuni AR, Fleming GJ. The effect of antiretroviral therapy on the prevalence of oral manifestations in HIV-infected patients: a UK study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2001; 92: 623-8.
2. Nicolatou-Galitis O, Velegraki A, Paikos S et al. Effect of PI-HAART on the prevalence of oral lesions in HIV-1 infected patients. A Greek study. Oral Dis 2004; 10: 145-50.
3. Skiest DJ, Vazquez JA, Anstead GM et al. Posaconazole for the treatment of azole-refractory oropharyngeal and esophageal candidiasis in subjects with HIV infection. Clin Infect Dis 2007; 44: 607-14.
4. Cornely OA, Maertens J, Winston DJ et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007; 356: 348-59.
5. Ullmann AJ, Lipton JH, Vesole DH et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007; 356: 335-47.
6. Krieter P, Flannery B, Musick T et al. Disposition of posaconazole following single-dose oral administration in healthy subjects. Antimicrob Agents Chemother 2004; 48: 3543-51.
7. Ghosal A, Hapangama N, Yuan Y et al. Identification of human UDP-glucuronosyltransferase enzyme(s) responsible for the glucuronidation of posaconazole (Noxafil). Drug Metab Dispos 2004; 32: 267-71.
8. Wexler D, Courtney R, Richards W et al. Effect of posaconazole on cytochrome P450 enzymes: a randomized, open-label, two-way crossover study. Eur J Pharm Sci 2004; 21: 645-53.
9. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. December 1 2009; 1-161. http://www.aidsinfo.nih.gov/ContentFiles/ AdultandAdolescentGL.pdf (29 December 2009, date last accessed).
10. FDA. Lexiva; Prescribing Information 11-09-2009. http://www. accessdata.fda.gov/scripts/cder/drugsatfda/ (29 December 2009, date last accessed).
11. Yeh RF, Gaver VE, Patterson KB et al. Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers. J Acquir Immune Defic Syndr 2006; 42: 52-60.
12. van der Lee MJ, Dawood L, ter Hofstede HJ et al. Lopinavir/ritonavir reduces lamotrigine plasma concentrations in healthy subjects. Clin Pharmacol Ther 2006; 80: 159-68.
13. Burger D, Huisman A, Van Ewijk N et al. The effect of atazanavir and atazanavir/ritonavir on UDP-glucuronosyltransferase using lamotrigine as a phenotypic probe. Clin Pharmacol Ther 2008; 84: 698-703.
14. Foisy MM, Yakiwchuk EM, Hughes CA. Induction effects of ritonavir: implications for drug interactions. Ann Pharmacother 2008; 42: 1048-59.
15. Droste JA, Verweij-van Wissen CP, Burger DM. Simultaneous determination of the HIV drugs indinavir, amprenavir, saquinavir, ritonavir, lopinavir, nelfinavir, the nelfinavir hydroxymetabolite M8, and nevirapine in human plasma by reversed-phase high-performance liquid chromatography. Ther Drug Monit 2003; 25: 393-9.
16. Aarnoutse RE, Verweij-van Wissen CP, van Ewijk-Beneken EWJ et al. International interlaboratory quality control program for measurement of antiretroviral drugs in plasma. Antimicrob Agents Chemother 2002; 46: 884-6.
17. Droste JA, Aarnoutse RE, Koopmans PP et al. Evaluation of antiretroviral drug measurements by an interlaboratory quality control program. J Acquir Immune Defic Syndr 2003; 32: 287-91.
18. Brüggemann RJ, Touw DJ, Aarnoutse RE et al. International interlaboratory proficiency testing program for measurement of azole antifungal plasma concentrations. Antimicrob Agents Chemother 2009; 53: 303-5.
19. van der Lee MJ, Blenke AA, Rongen GA et al. Interaction study of the combined use of paroxetine and fosamprenavir-ritonavir in healthy subjects. Antimicrob Agents Chemother 2007; 51: 4098-104.
20. Courtney R, Pai S, Laughlin M et al. Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults. Antimicrob Agents Chemother 2003; 47: 2788-95.
21. Courtney R, Wexler D, Radwanski E et al. Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults. Br J Clin Pharmacol 2004; 57: 218-22.
22. US Department of Health and Human Services, Center for Drug Evaluation and Research, Food and Drug Administration. Guidance for Industry. Statistical approaches to establishing bioequivalence. 2001. http://www.fda.gov/cder/guidance/index.htm (29 December 2009, date last accessed).
23. Waters LJ, Moyle G, Bonora S et al. Abacavir plasma pharmacokinetics in the absence and presence of atazanavir/ritonavir or lopinavir/ritonavir and vice versa in HIV-infected patients. Antivir Ther 2007; 12: 825-30.
24. Luber A, Slowinski D, Acosta E et al. Steady-state pharmacokinetics (PK) of fosamprenavir (FPV) and raltegravir (RAL) alone and combined with unboosted and ritonavir-boosted FPV. In: Abstracts of the Forty-ninth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, 2009. Abstract A1-1297. p. 297. American Society for Microbiology, Washington, DC, USA.
25. Wire MB, Shelton MJ, Studenberg S. Fosamprenavir: clinical pharmacokinetics and drug interactions of the amprenavir prodrug. Clin Pharmacokinet 2006; 45: 137-68.
26. Krishna G, Moton A, Ma L et al. Effects of oral posaconazole on the pharmacokinetics of atazanavir alone and with ritonavir or with 2194 efavirenz in healthy adult volunteers. J Acquir Immune Defic Syndr 2009; 51: 437-44.
27. EMEA. Noxafil; Summary of Product Characteristics 27-01-2009. http://www.emea.europa.eu/humandocs/Humans/EPAR/noxafil/noxafil.htm (29 December 2009, date last accessed).
28. Huang L, Wring SA, Woolley JL et al. Induction of P-glycoprotein and cytochrome P450 3A by HIV protease inhibitors. Drug Metab Dispos 2001; 29: 754-60.
29. Krishna G, Moton A, Ma L et al. Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. Antimicrob Agents Chemother 2009; 53: 958-66.
30. Speight M, Holford HG. Avery's Drug Treatment, 4th edn. Hoboken: Wiley-Blackwell, 1997.
31. EMEA. Telzir; Summary of Product Characteristics 17-12-2009. http://www.emea.europa.eu/htms/human/EPAR/telzir/telzir.htm (29 December 2009, date last accessed).
32. Wire MB, Baker KL, Jones LS et al. Ritonavir increases plasma amprenavir (APV) exposure to a similar extent when coadministered with either fosamprenavir or APV. Antimicrob Agents Chemother 2006; 50: 1578-80.
33. Wood R, Arasteh K, Stellbrink HJ et al. Six-week randomized controlled trial to compare the tolerabilities, pharmacokinetics, and antiviral activities of GW433908 and amprenavir in human immunodeficiency virus type 1-infected patients. Antimicrob Agents Chemother 2004; 48: 116-23.